ReNeuron encouraged by progress in stroke and RP treatments – Proactive Investors Australia

What the company does

Human retinal progenitor cells (hRPC)

Human retinal progenitor cells differentiate into components of the retina.

Reneuron has developed the ability to scale up the manufacturing of hRPCs using a patented low-oxygen cell expansion technology.

The hRPC cell therapy candidate is being evaluated in an ongoing phase I/IIa clinical trial in the US in subjects with a blindness-causing inherited retinal disease, retinitis pigmentosa (RP).

CTX Cells

CTX cell therapy candidate is a treatment for patients left disabled by the effects of a stroke.

Reneurons product is a standardised, clinical and commercial-grade cell therapy product capable of treating all eligible patients presenting with the diseases targeted, without the need for additional immunosuppressive drug treatments.

Data from the Phase II PISCES trial indicated CTX therapy was safe and well-tolerated and produced clinically meaningful and sustained improvement in the level of disability and dependence as well as motor function.

Exosome platform

Exosomes are nanoparticles, released by cells, and contain a number of active proteins and micro RNAs, which are short non-coding RNAs capable of regulating gene expression, that arebelieved to play a key role in cell-to-cell communication.

ExoPr0, Reneurons first CTX-derived exosome therapeutic candidate, has demonstrated potential as both a novel therapeutic candidate as well as a drug delivery vehicle

hRPC

's ()human retinal progenitor cells (hRPC) have scored some early success.

A Phase I/II assessment of a very small group of sufferers of a blindness-causing disease called retinitis pigmentosa saw a significant improvement in vision after treatment.

Six months after treatment there was a mean improvement of 18.5per treated eye, with a mean improvement of 12 letters per treated eye after nine months, whereasinexorable disease progression is the norm for this disease.

With a total of 22 patients now treated and the study still ongoing, ReNeuron said the efficacy in subsequent patients was seen but at a lower rate and magnitude, with improvement in visual acuity ranging from +5 to +11 letters in the treated eye threemonths after treatment.

In February, clinicaldata from the PISCES II clinical trial were published in peer-reviewedJournal of Neurology, Neurosurgery, and Psychiatry.

CTX

A peer journal review published in May indicated a CTX human neural stem cell line can rescue deficits associated with an accepted animal model of Huntington's disease, a progressive genetic brain disorder.

ReNeuron has previously presented data demonstrating that its CTX stem cell line, currently undergoing clinical evaluation for the treatment of stroke disability, can cause functional and behavioural recovery in animal models of ischemic (restriction of blood supply) injury.

The new data showed that implantation of CTX cells into a model of Huntington's disease can reduce inflammation, glial scar formation and induce host neurogenesis (the generation of new brain cells) leading to a recovery in behavioural deficits.

Coronavirus

In April, Reneuron said it haddeveloped a line of the human exosomes that can deliver a medically relevant payload: Viral vaccines thatmight help in the fight against coronavirus.

The stem cell specialist added that the disruption from lockdowns would inevitably lead to delays in the recruitment of patients for trials of its treatments for stroke disability and retinitis pigmentosa (RP).

It said it will update on how this will affect the release of top-line data from the two studies once it knows the full impact of the restrictions.

See original here:
ReNeuron encouraged by progress in stroke and RP treatments - Proactive Investors Australia

Alternative and Complementary Treatments for Cancer – HealthCentral.com

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

Link:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -…

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Wei Li as acting Chief Scientific Officer (CSO), effective June 1, 2020.

During her biotech career, Dr. Li co-founded two companies and built up extensive expertise in all aspects of drug research and development, including preclinical development and pharmacology, clinical development and operations, regulatory affairs, biomarker development and biomanufacturing.

Most recently, Dr. Li was Chief Development Officer at OliX Pharmaceuticals, a leading public South Korean biotech company developing siRNA therapeutics for multiple indications. She also served as Executive Vice President, Product Development at Boston Biomedical, Inc (BBI) from 2007-2018, playing a key role in growing it from a start-up in 2007 to an industry leader in cancer stem cell research, including through the acquisition by Sumitomo Dainippon in 2012. Dr. Li led the development of napabucasin (BBI608), a first-in-class drug selected as one of the worlds top ten cancer drugs in late stage clinical development by Fierce Biotech. Dr. Li started her career at ArQule, a public biotech company developing targeted therapies for hematological malignancies and acquired by Merck &Co in 2019.

Wei Li holds a PhD in Molecular Virology from Georgia State University and completed her Postdoctoral Training at Harvard Medical School.

Dr. Wei Li said: I am thrilled to be joining the great team of scientists and entrepreneurs at Cytovia Therapeutics. NK-cell based therapeutics are at an inflection point. Initial clinical trials have shown promising safety and efficacy. Off-the-shelf manufacturing promises broader and faster patient access. Cytovia Therapeutics has an excellent iPSC CAR-NK platform and a strong pipeline in both hematological and solid tumors. It is tremendously exciting to be involved in this stage of the companys development.

Dr Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc said: We are delighted to welcome Dr. Wei Li to Cytovia Therapeutics as Chief Scientific Officer. Wei has a stellar track record of bringing innovative oncology drugs from discovery to clinical development. Her operational excellence and entrepreneurial drive will be critical to help bring multiple iPSC CAR NK therapeutics to initial clinical trials starting in 2021.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more at http://www.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVP corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Read the original:
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -...

Tiny Human Livers Grown in The Lab Have Been Successfully Transplanted Into Rats – ScienceAlert

Scientists have successfully transplanted functional miniature livers into rats, after growing the bioengineered organs in the lab from reprogrammed human skin cells.

The experiment, which gave the animals working liver organs, could lay the groundwork for future treatments to address terminal liver failure a disease that claims the lives of over 40,000 people in the US every year.

While there's still a lot of work to be done before the technique can directly aid human patients, the researchers say their proof of concept may help underpin a future alternative to liver transplants, which are often incredibly expensive procedures to perform, in addition to being strictly limited by donor supply.

Another positive outcome would be using the approach to temporarily augment failing liver function in patients, lengthening people's lives while they're on the waiting list for these vital organs: a situation facing about 14,000 Americans at any given moment, most of whom won't ever receive a transplant.

"The long-term goal is to create organs that can replace organ donation, but in the near future, I see this as a bridge to transplant," explains pathologist Alejandro Soto-Gutirrez from the University of Pittsburgh.

"For instance, in acute liver failure, you might just need hepatic boost for a while instead of a whole new liver."

To grow their mini livers, the researchers took human skin cells donated by volunteers and reverted them to a stem cell state, known as induced pluripotent stem cells, from which other kinds of cell types can be derived.

The researchers then induced differentiation in the cells with the aid of hormones and other chemicals, prompting them to become liver cells, which were cultured in the lab.

While it ordinarily takes two years for a human's liver to mature from the moment of their birth, the researchers were able to grow their miniature analogues in only a matter of weeks, seeding the grown cells on a rat liver scaffold that had been stripped of its rat cells.

While previous experimental liver graft research has incorporated rodent cells onto the scaffold, here the researchers used the human stem cells to populate the liver's functional tissue, along with its vascular system and bile duct network.

When transplanted into five rats, the mini livers appeared to be functional. After four days - at which point the animals were sacrificed and dissected - tests revealed that the bioengineered livers secreted bile acids and urea; human liver proteins in the animals' blood were another sign that the organs were working.

Not that the transplants functioned perfectly. Evidence of poor blood flow into the graft, in addition to thrombosis and ischemia, reveals there are still serious difficulties in properly connecting grafts like these to an animal's vascular network.

Nonetheless, it's still a remarkable achievement. For a short time, five rats lived their lives with miniature human livers, which isn't something that's ever been demonstrated before, and it could bring us closer to employing the same techniques for the benefit of human patients one day.

That day might be a long time away (perhaps a decade off, the researchers suggest), although it depends on a huge range of future experiments succeeding, including demonstrating that these kinds of engineered transplants are safe for humans, which remains to be seen.

In the meantime, methods like this including work pioneered by the same laboratory last year could enable the use of such mini organs to study simulated diseases and test different treatment options.

"I believe it's a very important step because we know it can be done," Soto-Gutirrez explained to Inverse. "You can make a whole organ that can be functional from one cell of the skin."

The findings are reported in Cell Reports.

View post:
Tiny Human Livers Grown in The Lab Have Been Successfully Transplanted Into Rats - ScienceAlert

Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts – Texas A&M University Today

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

The rest is here:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today

Latest Update 2020: Canine Stem Cell Therapy Market by COVID19 Impact Analysis And Top Manufacturers: VETSTEM BIOPHARMA, Cell Therapy Sciences,…

InForGrowth Market Research offers a most recent distributed report on Global Canine Stem Cell Therapy industry examination and figure 2019-2025 conveying key bits of knowledge and giving an upper hand to customers through a point by point report. The report contains XX pages which profoundly displays on current market investigation situation, up and coming just as future chances, income development, evaluating and gainfulness. The Global pandemic of COVID19 calls for redefining of business strategies. This Canine Stem Cell Therapy Market report includes the impact analysis necessary for the same

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Canine Stem Cell Therapy Market 2020. https://inforgrowth.com/CovidImpact-Request/6322118/canine-stem-cell-therapy-market

Worldwide Canine Stem Cell Therapy Market inspect reports consolidate market designs nuances, genuine scene, feature assessment, cost structure, capability, bargains, net advantage, and movement and measuring of business.

Major Key players covered in this report:VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet, .

Canine Stem Cell Therapy Market Potential

The overall market is set up for energetic advancement with progressively moving of various gathering methodology to more affordable objectives in rising economies. Another factor booked to altogether bolster the market is fused programming game plans disposing of the prerequisite for different models and thing survey concerns.Premium Insights on Canine Stem Cell Therapy Market 2020 with Market Players Positioning; Download Free Sample Copy: https://inforgrowth.com/sample-request/6322118/canine-stem-cell-therapy-market

The Worldwide Market forGlobal Canine Stem Cell Therapy marketis relied upon to develop at a CAGR of generally xx% throughout the following five years, will arrive at xx million US$ in 2026, from xx million US$ in 2019, as per another research.

This report focuses around the Canine Stem Cell Therapy Market in the worldwide market, particularly in North America, Europe and Asia-Pacific, South America, Middle East, and Africa. This Canine Stem Cell Therapy Market report sorts the market dependent on the manufacturer, region, type, and application.

Major Classifications of Canine Stem Cell Therapy Market:

By Product Type: Allogeneic Stem Cells, Autologous Stem cells

By Applications: Veterinary Hospitals, Veterinary Clinics, Veterinary Research Institutes

The study objectives of Canine Stem Cell Therapy Market Report are:

Regional Analysis of Canine Stem Cell Therapy Market:

The report additionally provides a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimation to analyze investment possibilities and destiny growth. The key players and distinctive affecting components are examined completely on this report.

Enquire before Purchase this report at https://inforgrowth.com/enquiry/6322118/canine-stem-cell-therapy-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See the rest here:
Latest Update 2020: Canine Stem Cell Therapy Market by COVID19 Impact Analysis And Top Manufacturers: VETSTEM BIOPHARMA, Cell Therapy Sciences,...

Potential impact of coronavirus outbreak on Stem Cell Antibody Market: Opportunities and Forecast Assessment, 2019-2025 – 3rd Watch News

The research study presented in this report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Stem Cell Antibody Market. The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Stem Cell Antibody market. We have also provided absolute dollar opportunity and other types of market analysis on the global Stem Cell Antibody market.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Stem Cell Antibody market. All findings and data on the global Stem Cell Antibody market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Stem Cell Antibody market available in different regions and countries.

The report on the Stem Cell Antibody market provides a birds eye view of the current proceeding within the Stem Cell Antibody market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Stem Cell Antibody market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2548440&source=atm

The authors of the report have segmented the global Stem Cell Antibody market as per product, application, and region. Segments of the global Stem Cell Antibody market are analyzed on the basis of market share, production, consumption, revenue, CAGR, market size, and more factors. The analysts have profiled leading players of the global Stem Cell Antibody market, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects.

The following manufacturers are covered:Thermo Fisher Scientific, Inc. (U.S.)Merck Group (Germany), Abcam plc (U.K.)Becton, Dickinson and Company (U.S.)Bio-Rad Laboratories, Inc. (U.S.)Cell Signaling Technology, Inc. (U.S.)Agilent Technologies, Inc. (U.S.)F. Hoffmann-La Roche Ltd (Switzerland)Danaher Corporation (U.S.)GenScript (U.S.), PerkinElmer, Inc. (U.S.)Lonza (Switzerland), and BioLegend, Inc. (U.S.)

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypePrimary AntibodiesSecondary Antibodies

Segment by ApplicationProteomicsDrug DevelopmentGenomics

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2548440&source=atm

Stem Cell Antibody Market Size and Forecast

In terms of region, this research report covers almost all the major regions across the globe such as North America, Europe, South America, the Middle East, and Africa and the Asia Pacific. Europe and North America regions are anticipated to show an upward growth in the years to come. While Stem Cell Antibody Market in Asia Pacific regions is likely to show remarkable growth during the forecasted period. Cutting edge technology and innovations are the most important traits of the North America region and thats the reason most of the time the US dominates the global markets. Stem Cell Antibody Market in South, America region is also expected to grow in near future.

The Stem Cell Antibody Market report highlights is as follows:

This Stem Cell Antibody market report provides complete market overview which offers the competitive market scenario among major players of the industry, proper understanding of the growth opportunities, and advanced business strategies used by the market in the current and forecast period.

This Stem Cell Antibody Market report will help a business or an individual to take appropriate business decision and sound actions to be taken after understanding the growth restraining factors, market risks, market situation, market estimation of the competitors.

The expected Stem Cell Antibody Market growth and development status can be understood in a better way through this five-year forecast information presented in this report

This Stem Cell Antibody Market research report aids as a broad guideline which provides in-depth insights and detailed analysis of several trade verticals.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2548440&licType=S&source=atm

Visit link:
Potential impact of coronavirus outbreak on Stem Cell Antibody Market: Opportunities and Forecast Assessment, 2019-2025 - 3rd Watch News

Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future – Cole of Duty

A synopsis of the global canine stem cell therapy market with reference to the global healthcare pharmaceutical industry

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare Current expenditure on health, % of gross domestic product Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs) Annual growth rate of current expenditure on health, per capita, in real terms Out-of-pocket expenditure, % of current expenditure on health Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs) Physicians, Density per 1000 population (head counts) Nurses, Density per 1000 population (head counts) Total hospital beds, per 1000 population Curative (acute) care beds, per 1000 population Medical technology, Magnetic Resonance Imaging units, total, per million population Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

Get Sample Copy of this report at https://www.xploremr.com/connectus/sample/2360

XploreMR utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Please note that these are the partial steps that are being followed while developing the market size. Besides this, forecasting will be done based on our internal proprietary model which also uses different macro-economic factors such as per capita healthcare expenditure, disposable income, industry based demand driving factors impacting the market and its forecast trends apart from disease related factors.

Browse Full Report at https://www.xploremr.com/report/2360/canine-stem-cell-therapy-market

Standard Report Structure Executive Summary Market Definition Macro-economic analysis Parent Market Analysis Market Overview Forecast Factors Segmental Analysis and Forecast Regional Analysis Competition Analysis

Target Audience Production Companies Suppliers Channel Partners Marketing Authorities Subject Matter Experts Research Institutions Financial Institutions Market Consultants Government Authorities

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type: Allogeneic Stem Cells Autologous Stem cells

Application: Arthritis Dysplasia Tendonitis Lameness Others

End User: Veterinary Hospitals Veterinary Clinics Veterinary Research Institutes

Region: North America Latin America Europe Asia Pacific Japan Middle East & Africa

Buy Full Report at https://www.xploremr.com/cart/2360/SL

About Us

XploreMR is one of the worlds leading resellers of high-quality market research reports. We feature in-depth reports from some of the worlds most reputed market research companies and international organizations. We serve across a broad spectrum from Fortune 500 to small and medium businesses. Our clients trust us for our unwavering focus onquality and affordability. We believe high price should not be a bottleneck for organizations looking to gain access to quality information.

Contact us:XploreMR111 North Market Street, Suite 300,San Jose, CA 95113, United StatesPh.No: +16692840108

More here:
Canine Stem Cell Therapy Market Will Make a Huge Impact in Near Future - Cole of Duty

BHU prepares to be amongst top 500 global universities – Hindustan Times

With an aim to be a part of top 500 universities of the world, Banaras Hindu University (BHU) is expanding its international hostel, building smart classrooms, upgrading graduate and postgraduate laboratories, and beautifying its campus under the institute of excellence (IoE) scheme, said BHU public relations officer Dr Rajesh Singh.

Giving details of achievements of BHU in last one year, Dr Singh said that the government had sanctioned Rs 1000 crore under IoE scheme a few months ago to the university for upgrading infrastructure, academic and research facilities, laboratories, central and departmental libraries within five years.

Work has already started for upgrading academic and research facilities. The international hostel of 110 rooms is almost ready. It will help the university attract more foreign students.

He said with the financial support of the ministry of human resource development and union ministry of health and family welfare, a super speciality block worth Rs 200 crore has been built in BHU.

After being inaugurated by Prime Minister Narendra Modi, it is already functional. At present, it is providing medical services to Covid-19 patients. It is equipped with operation theatres, and biochemistry lab and pathology.

Moreover, bone marrow transplant and stem cell research centre have also been set up, construction of regional eye centre with an estimated cost of Rs 38.5 crore is about to be completed.

Singh said that with the financial support of union human resource development ministry, a central discovery centre, equipped with state of the art facilities, for research in basic and practical science is also being set up.

A SATHI centre with an estimated cost of Rs 125 crore is being set up in BHU. Under one roof, there will be facilities for innovation, entrepreneurship and development of startups.

He said that a centre for Vedic science has been set up in the university for research and to establish a link between ancient Indian knowledge and modern science. The centre will also work for reestablishing the excellent sources of knowledge, Vedas and its wide area and will also study their effect in understanding modern science and technology.

BHU has also signed an MoU with solar energy corporation for setting up a solar energy centre and a green energy centre for study in this field.

Dr Singh said that 369 research projects worth over Rs 157 crore are underway in the university.

More:
BHU prepares to be amongst top 500 global universities - Hindustan Times

Global Stem Cell Antibody Market Insights 2020 Demand Growing Rapidly with Major Player- Thermo Fisher Scientific, Merck Group, Abcam plc – Cole of…

Stem Cell Antibody Market Research Report released by Research N Reports is a tool to inform businesses on histories, current trends and ample research to navigate through its complexities. Effective business strategies of the leading key players and startups have been explained in detail. The Stem Cell Antibody Market is expected to reach at a huge CAGR during the forecast period.

The research report details the classification of the Stem Cell Antibody Market. The Stem Cell Antibody Market is divided into several segments based on materials, types, applications, and end-users. The report also includes a geographic analysis of the global market. The vital information mentioned in the research report will help to predict the future of the global market.

For Sample Copy of this report: https://www.researchnreports.com/request_sample.php?id=790931

The report delivers a comprehensive overview of the crucial elements of the Market and elements such as drivers, restraints, current trends of the past and present times, supervisory scenario, and technological growth. A thorough analysis of these elements has been accepted for defining the future growth prospects of the global Stem Cell Antibody Market.

Key Players:

Thermo Fisher Scientific, Inc. (U.S.), Merck Group (Germany), Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Cell Signaling Technology, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.)

This statistical surveying research report on the Stem Cell Antibody is an all-inclusive study of the business sectors latest outlines, industry growth drivers, and inadequacies. It gives market forecasts for the coming years. It contains an examination of the latest progressions in technology, Porters five force analysis and dynamic profiles of exclusive industry competitors. The report besides conveys an investigation of trivial and full-scale factors prosecuting for the new candidates in the market and the ones currently in the market.

Ask for Discount on this Report: https://www.researchnreports.com/ask_for_discount.php?id=790931

Reasons for Buying this Report:

Across the globe, several regions like North America, Latin America, Asia-Pacific, Europe, and Africa have been studied on the basis of sale and profit margin. Some significant key players have been profiled to get informative data to make informed decisions in the businesses. It makes use of info graphics, graphs, charts, tables, and pictures. For an effective and accurate business outlook, the report on the global Stem Cell Antibody Market examined details of the changing trends adopted by the top level companies.

Get Complete [emailprotected] https://www.researchnreports.com/enquiry_before_buying.php?id=790931

About Us:

Research N Reports is a new age market research firm where we focus on providing information that can be effectively applied. Today being a consumer driven market, companies require information to deal with the complex and dynamic world of choices. Where relying on a sound board firm for your decisions becomes crucial. Research N Reports specializes in industry analysis, market forecasts and as a result getting quality reports covering all verticals, whether be it gaining perspective on current market conditions or being ahead in the cut throat Global competition. Since we excel at business research to help businesses grow, we also offer consulting as an extended arm to our services which only helps us gain more insight into current trends and problems. Consequently we keep evolving as an all-rounder provider of viable information under one roof.

Contact:

Sunny Denis

Research N Reports

10916, Gold Point Dr,

Houston, TX, Pin 77064,

+1 510-402-1213,

[emailprotected]

https://www.researchnreports.com

Go here to read the rest:
Global Stem Cell Antibody Market Insights 2020 Demand Growing Rapidly with Major Player- Thermo Fisher Scientific, Merck Group, Abcam plc - Cole of...